Rivaroxaban in Peripheral Artery Disease after Revascularization

RCT (n=6,564) found that rivaroxaban plus aspirin was superior to aspirin plus placebo for a composite cardiovascular efficacy outcome (multiple cardiovascular outcomes including cardiovascular death) – 17.3% vs 19.9%, HR 0.85, 95% CI 0.76-0.96).

SPS commentary:

The incidence of major bleeding according to the Thrombolysis in Myocardial Infarction classification was not different between groups, however the incidence of major bleeding for rivaroxaban was greater than placebo under the International Society on Thrombosis and Haemostasis definition (5.94% vs 4.05%, HR 1.42, 95% CI 1.10-1.84).


New England Journal of Medicine